MT2023-31: A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Status: Recruiting

Description:

This research study is designed to compare a new gene therapy, known as OTL-203 (study drug), with a standard treatment called “allogeneic hematopoietic stem cell transplant” (allo-HSCT), to find out which is better for the treatment of MPS-IH.

I'm interested

Sex: Male or Female

Age Group: Up to 18 years old

This study is NOT accepting healthy volunteers

Inclusion Criteria:

• at least 28 days old to no more than 30 months old
• confirmed laboratory diagnosis of MPS-IH
• evidence of altered GAG metabolism
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

• previous allo-HSCT or gene therapy
• diagnosis of HIV, Hepatitis B, Hepatitis C, or Mycoplasma
• history of uncontrolled seizures
• contraindications for MRI scans
• study staff will review additional exclusion criteria

Interventions:

Genetic: Active Comparator: Allo-HSCT, Genetic: Experimental: OTL-203

Conditions:

Rare Diseases

Keywords:

Hurler syndrome, MPS-IH, mucopolysaccharidosis type I

Study Contact: Ashish Gupta - gupta461@umn.edu

Principal Investigator: Ashish Gupta

Phase: PHASE3

IRB Number: STUDY00020015

See this study on ClinicalTrials.gov

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.

MT2023-31: A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Email this study information to me

Contact the study team